BioSpace News Archive

SpringWorks Therapeutics, Inc. today announced that management will participate in a Fireside Chat at the 12th Annual Wedbush PacGrow Healthcare Conference on Wednesday, August 11th at 9:45AM ET.

Angion Biomedica Corp announced positive results from its Phase 1 study in healthy volunteers for ANG-3070, a novel oral tyrosine kinase receptor inhibitor being developed for the treatment of fibrotic diseases.

RELIEF THERAPEUTICS Holding AG reported that, via its newly acquired subsidiary, AdVita Lifescience GmbH, the Company has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for RLF-100, an inhaled formulation in development for the treatment of sarcoidosis.

According to the report, the global dengue vaccines market was valued at US$ 0.4 Bn in 2020 and is projected to expand at a CAGR of 11% from 2021 to 2031.

Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform’s award-winning CESS® technology can deliver to its drug development projects.

Outlook Therapeutics, Inc. announced positive clinical and highly statistically significant top-line results from its pivotal Phase 3 NORSE TWO safety and efficacy trial evaluating ONS-5010 / LYTENAVA™ for treatment of neovascular age-related macular degeneration.

CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that Brazil’s regulatory authority ANVISA has approved the previously submitted clinical trial protocol to commence patient enrollment in its CD17 trial for severe COVID-19 patients.

SpringWorks Therapeutics, Inc. announced that the Company will be evaluating mirdametinib, an investigational MEK inhibitor, in a platform study sponsored by Memorial Sloan Kettering Cancer Center and supported by SpringWorks exploring the compound both as a monotherapy and as a combination therapy in advanced solid tumors harboring MAPK-activating mutations.

Zimmer Biomet Holdings, Inc. reported financial results for the quarter ended June 30, 2021.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced participation in the following investor conferences in August